DE60238486D1 - Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen - Google Patents

Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen

Info

Publication number
DE60238486D1
DE60238486D1 DE60238486T DE60238486T DE60238486D1 DE 60238486 D1 DE60238486 D1 DE 60238486D1 DE 60238486 T DE60238486 T DE 60238486T DE 60238486 T DE60238486 T DE 60238486T DE 60238486 D1 DE60238486 D1 DE 60238486D1
Authority
DE
Germany
Prior art keywords
cells
hematopoetic
genetic modification
temporary
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60238486T
Other languages
English (en)
Inventor
Geoffery P Symonds
Rafael Amado
Lun-Quan Sun
Janet Macpherson
Greg Fanning
Wayne Gerlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johnson and Johnson Research Pty Ltd
Original Assignee
Johnson and Johnson Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Research Pty Ltd filed Critical Johnson and Johnson Research Pty Ltd
Application granted granted Critical
Publication of DE60238486D1 publication Critical patent/DE60238486D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60238486T 2001-07-10 2002-07-10 Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen Expired - Lifetime DE60238486D1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US30412701P 2001-07-10 2001-07-10
US30428301P 2001-07-10 2001-07-10
US34348401P 2001-12-21 2001-12-21
US38606302P 2002-06-04 2002-06-04
PCT/US2002/021907 WO2003006691A1 (en) 2001-07-10 2002-07-10 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells

Publications (1)

Publication Number Publication Date
DE60238486D1 true DE60238486D1 (de) 2011-01-13

Family

ID=27501852

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60238486T Expired - Lifetime DE60238486D1 (de) 2001-07-10 2002-07-10 Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen

Country Status (16)

Country Link
US (2) US7345025B2 (de)
EP (2) EP1414996B1 (de)
JP (2) JP5179697B2 (de)
KR (1) KR101015913B1 (de)
CN (2) CN101926824A (de)
AT (1) ATE490322T1 (de)
AU (1) AU2002316640C1 (de)
BR (1) BR0211079A (de)
CA (1) CA2453531A1 (de)
DE (1) DE60238486D1 (de)
DK (1) DK1414996T3 (de)
HK (1) HK1065074A1 (de)
IL (2) IL159637A0 (de)
MX (1) MXPA04000268A (de)
NZ (1) NZ530624A (de)
WO (1) WO2003006691A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
CA2279673A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acids for therapeutic and diagnostic uses
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
KR20040084885A (ko) * 2001-07-10 2004-10-06 존슨 앤드 존슨 리서치 피티와이 리미티드 형질도입된 조혈 선조 세포의 제조 방법
NZ530624A (en) 2001-07-10 2009-02-28 Johnson & Johnson Res Pty Ltd Compositions comprising C34+ hematopoietic progenitor cells transformed with an anti-viral agent for treating HIV
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
ATE439041T1 (de) 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
DE10212892A1 (de) * 2002-03-20 2003-10-09 Basf Plant Science Gmbh Konstrukte und Verfahren zur Regulation der Genexpression
DE10224750A1 (de) 2002-06-04 2003-12-24 Fresenius Medical Care De Gmbh Vorrichtung zur Behandlung einer medizinischen Flüssigkeit
US20040197316A1 (en) * 2003-02-06 2004-10-07 Tsokos George C. Novel method for the treatment of systemic lupus erythematosus
WO2004090121A2 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0410130D0 (en) * 2004-05-06 2004-06-09 Molmed Spa Cell preparation
US7935074B2 (en) * 2005-02-28 2011-05-03 Fresenius Medical Care Holdings, Inc. Cassette system for peritoneal dialysis machine
US8197231B2 (en) 2005-07-13 2012-06-12 Purity Solutions Llc Diaphragm pump and related methods
US20070041948A1 (en) * 2005-07-20 2007-02-22 Seoul National University Industry Foundation Method for culturing and proliferating hematopoietic stem cells and progenitor cells using human endometrial cells
US20080038231A1 (en) * 2006-06-15 2008-02-14 Rodgerson Denis O Processing procedure for peripheral blood stem cells
JP2011160661A (ja) * 2008-06-02 2011-08-25 Kyowa Hakko Kirin Co Ltd 血球細胞の初期化法
US8112365B2 (en) * 2008-12-19 2012-02-07 Foster Scott C System and method for online employment recruiting and evaluation
US20100210989A1 (en) 2008-12-23 2010-08-19 Janet Lesley Macpherson Processing blood
US8192401B2 (en) * 2009-03-20 2012-06-05 Fresenius Medical Care Holdings, Inc. Medical fluid pump systems and related components and methods
US20120034197A1 (en) * 2009-04-09 2012-02-09 Stemcyte Inc. Hiv-resistant stem cells and uses thereof
CA2767668C (en) 2009-07-15 2017-03-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US8720913B2 (en) 2009-08-11 2014-05-13 Fresenius Medical Care Holdings, Inc. Portable peritoneal dialysis carts and related systems
WO2012074068A1 (ja) * 2010-12-01 2012-06-07 日産化学工業株式会社 ピラゾール化合物による造血幹細胞の製造方法
DE102010053973A1 (de) 2010-12-09 2012-06-14 Fresenius Medical Care Deutschland Gmbh Medizinisches Gerät mit einer Heizung
WO2012087798A2 (en) 2010-12-20 2012-06-28 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9624915B2 (en) 2011-03-09 2017-04-18 Fresenius Medical Care Holdings, Inc. Medical fluid delivery sets and related systems and methods
WO2012154352A1 (en) 2011-04-21 2012-11-15 Fresenius Medical Care Holdings, Inc. Medical fluid pumping systems and related devices and methods
US9186449B2 (en) 2011-11-01 2015-11-17 Fresenius Medical Care Holdings, Inc. Dialysis machine support assemblies and related systems and methods
US9610392B2 (en) 2012-06-08 2017-04-04 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
US9500188B2 (en) 2012-06-11 2016-11-22 Fresenius Medical Care Holdings, Inc. Medical fluid cassettes and related systems and methods
KR20240045263A (ko) * 2012-09-07 2024-04-05 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
RU2673156C2 (ru) * 2012-11-05 2018-11-22 Ридженерон Фармасьютикалз, Инк. Генетически модифицированные не относящиеся к человеческому роду животные и способы их применения
US10077426B2 (en) 2012-12-06 2018-09-18 Enlivex Therapeutics Ltd Therapeutic apoptotic cell preparations, method for producing same and uses thereof
US9561323B2 (en) 2013-03-14 2017-02-07 Fresenius Medical Care Holdings, Inc. Medical fluid cassette leak detection methods and devices
US10117985B2 (en) 2013-08-21 2018-11-06 Fresenius Medical Care Holdings, Inc. Determining a volume of medical fluid pumped into or out of a medical fluid cassette
CN103471896A (zh) * 2013-09-09 2013-12-25 上海兰卫临床检验有限公司 革兰染色液质控品制备方法
US20200199534A1 (en) * 2017-04-27 2020-06-25 Fred Hutchinson Cancer Research Center Therapeutic formulations containing cd34+ stem cells derived from negative selection
WO2019099619A1 (en) * 2017-11-15 2019-05-23 Weird Science Llc Methods and compositions for non-myeloablative bone marrow reconstitution

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
DE3852539T3 (de) 1987-12-15 2005-08-04 Gene Shears Pty. Ltd. Ribozyme.
US5866701A (en) 1988-09-20 1999-02-02 The Board Of Regents For Northern Illinois University Of Dekalb HIV targeted hairpin ribozymes
US4978514A (en) 1989-09-12 1990-12-18 Fuel Tech, Inc. Combined catalytic/non-catalytic process for nitrogen oxides reduction
US5225337A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
US5500357A (en) 1990-11-02 1996-03-19 Agency Of Industrial Science & Technology, Ministry Of International Trade & Industry RNA transcription system using novel ribozyme
AU655279B2 (en) 1991-04-05 1994-12-15 Edison Animal Biotechnology Center Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
US5525468A (en) 1992-05-14 1996-06-11 Ribozyme Pharmaceuticals, Inc. Assay for Ribozyme target site
US5693535A (en) 1992-05-14 1997-12-02 Ribozyme Pharmaceuticals, Inc. HIV targeted ribozymes
US5911983A (en) 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
EP0652705B1 (de) 1992-06-29 2005-12-14 Gene Shears Pty Limited Nukleinsäuren und sie verwendende verfahren zur bekämpfung viraler pathogene
CA2154363A1 (en) 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
IL108719A0 (en) 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
DK1298208T3 (da) 1994-01-05 2006-07-24 Gene Shears Pty Ltd Ribozymer der er målrettet mod en HIV-tat-sekvens
US5712384A (en) * 1994-01-05 1998-01-27 Gene Shears Pty Ltd. Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US20020058636A1 (en) 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0821740A1 (de) 1995-04-20 1998-02-04 Chiron Corporation Hocheffiziente, ex-vivo, transduktion von hämatopoietischen stammzellen mit rekombinante xenotrope retroviren
US5741706A (en) * 1996-06-13 1998-04-21 Immusol, Incorporated Anti-HIV ribozymes
TWI239352B (en) 1997-07-23 2005-09-11 Takara Bio Inc Gene transfer method with the use of serum-free medium
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6060317A (en) 1998-08-11 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Method of transducing mammalian cells, and products related thereto
WO2000034495A2 (en) * 1998-12-04 2000-06-15 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
AU5403100A (en) * 1999-06-08 2000-12-28 Novartis Ag Enforced expression of bcl-xl
JP2004509120A (ja) 2000-09-13 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド カスパーゼ阻害剤およびそれらの用途
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
KR20040084885A (ko) 2001-07-10 2004-10-06 존슨 앤드 존슨 리서치 피티와이 리미티드 형질도입된 조혈 선조 세포의 제조 방법
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
NZ530624A (en) 2001-07-10 2009-02-28 Johnson & Johnson Res Pty Ltd Compositions comprising C34+ hematopoietic progenitor cells transformed with an anti-viral agent for treating HIV
KR100646702B1 (ko) * 2001-08-16 2006-11-17 에스케이씨 주식회사 홀 및/또는 그루브로 형성된 화학적 기계적 연마패드

Also Published As

Publication number Publication date
EP1414996A1 (de) 2004-05-06
CA2453531A1 (en) 2003-01-23
EP1414996B1 (de) 2010-12-01
EP1414996A4 (de) 2007-03-28
US20080044394A1 (en) 2008-02-21
JP5179697B2 (ja) 2013-04-10
MXPA04000268A (es) 2005-03-07
JP2005528319A (ja) 2005-09-22
ATE490322T1 (de) 2010-12-15
NZ530624A (en) 2009-02-28
AU2002316640C1 (en) 2009-01-29
JP2010077125A (ja) 2010-04-08
CN101926824A (zh) 2010-12-29
BR0211079A (pt) 2005-08-30
HK1065074A1 (en) 2005-02-08
IL159637A (en) 2013-07-31
IL159637A0 (en) 2004-06-01
WO2003006691A1 (en) 2003-01-23
DK1414996T3 (da) 2011-03-21
US7345025B2 (en) 2008-03-18
KR101015913B1 (ko) 2011-02-23
KR20040032852A (ko) 2004-04-17
US20040072771A1 (en) 2004-04-15
CN1553963A (zh) 2004-12-08
AU2002316640B2 (en) 2008-06-12
EP2322618A1 (de) 2011-05-18
US7776595B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
DE60238486D1 (de) Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
ATE419859T1 (de) Verwendung von probiotischen bakterien zur herstellung von topischen zusammensetzungen zum schutz der haut
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
WO2005032471A3 (en) Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
EP1196444B8 (de) Exendin-4 konjugate und ihre medizinische verwendung
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
SI1615952T1 (sl) Metoda zdravljenja vnetnih bolezni z uporabo specifičnih veznih sredstev humanega angiopoetin
BR0315689A (pt) Alvo para terapia de dano cognitivo
DE60233805D1 (de) Zusammensetzungen und verfahren zur isolierung, vermehrung und differenzierung nicht-embryonale menschlicher stammzellen und deren verwendungen
WO2002064096A3 (en) Methods of using pyrimidine-based antiviral agents
NO20055130D0 (no) Aminocykloheksyleter-forbindelser og deres anvendelse
NO20055941L (no) Anvendelse av en sammensetning omfattende en PDE4-inhibitor og en PDE5-inhibitor
EP1362127A4 (de) Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung
IL178094A0 (en) Improvements in or relating to compounds for use in the treatment of aids and other viral diseases and hiv-related infections and compositions containing such compounds, methods of treating such diseases and infections and methods of making such compounds and compositions
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
GB0211247D0 (en) Compositions and methods for treating or preventing convulsions or seizures
DE60335647D1 (de) Pyrroloquinoline quinone und ein betablocker zur behandlung von ischämie oder reperfusionsschäden
DK1793859T3 (da) Behandling af oral og intestinal mucositis ved indgivelse af humant IL-18
EA200601392A1 (ru) Способы и композиции для лечения липодистрофии
DE60042210D1 (de) Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
DE502004012196D1 (de) Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen
ATE398188T1 (de) Für akzessorische hiv proteine kodierende dna impfstoffe
ATE412423T1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion